Scientific Online Resource System

Varna Medical Forum

In vitro susceptibility of clinical isolates of Sotrophomonas maltophilia to antimicrobial agents

Milena Bozhkova, Temenuga Stoeva


The aim of this study was to test the susceptibity of 96 clincal isolates ofS.maltophiliato set of antimicrobial agents. The isolates were collected from patients, hospitalized in two Bulgarian University Hospitals (Varna, n=78 and Pleven, n=18) during the period 2007 - 2015. The antimicrobial susceptibility was studied by E-test and the results were interpreted according to EUCAST. The most active antibiotics (with the lowest level of resistance) were tigecycline (97.92%), trimethoprim/sulfametoxazole (95.84%) and doxycycline (92.71%). The highest rate of resistance was detected for ticarcillin/clavulanic acid (61.46%), followed by cefatzidime (56.25%) and chloramphenicol (55.21%).


Stenotrophomonas maltophilia, resistance, antimicrobial agents

Full Text


Събчева, С. Чувствителност към бе- та-лактамни антибиотици, ципрофлокса- цин и триметоприм-сулфаметоксазол на Stenotrophomonas maltophilia – причини- тел на инфекциозни процеси при болни със злокачествени новообразувания // Онкологичен преглед. 1998; 5: 8-12.

Chung HS, Hong SG, Kim YR, Shin KS, Whang DH, Ahn JY et al. Antimicrobial susceptibility of Stenotrophomonas maltophilia isolates from Korea, and the activity of antimicrobial combinations against the isolates. J Korean Med Sci. 2013; 28: 62-6.

European Committee on Antimicrobial Susceptibility Testing – EUCAST [Internet]. Expert rules in antimicrobial susceptibility testing Available from: http://www.eucast. org/expert_rules/.

Falagas ME, Vardakas KZ, Tsiveriotis KP, Triarides NA, Tansarli GS. Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections. Int J Antimicrob Agents. 2014; 44: 1-7.

Farrell DJ, Sader HS, Jones RN. Antimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections. Antimicrob Agents Chemother. 2010; 54: 2735-7.

Flores-Trevino S Gutiérrez-Ferman JL, Morfín-Otero R, Rodríguez-Noriega E, Estrada-Rivadeneyra D, Rivas-Morales C, еt al. Stenotrophomonas maltophilia in Mexico: antimicrobial resistance, biofilm formation and clonal diversity. J Med Microb. 2014; 63: 1524-30.

Jones R, Sader H, Beach M. Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18 569 strains non-fermentative Gram-negative bacilli isolated in the SENTRY Antimicrobial Surveillance Program (1997–2001). Int J Antimicrob Agents 2003; 22: 551-6.

Gales AC, Jones RN, Forward KR, Liñares J, Sader HS, Verhoef J. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY antimicrobial surveillance program (1997–1999). Clin Infect Dis. 2001; 32: 104–13.

Gales AC, Jones RN, Sader HS. Global assessment оf the antimicrobial activity of polymyxinB against 54731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004). Clin Microbiol Infect. 2006; 12: 315-21.

Mihaylova S, Sredkova M, Svensson L, Edward M. Emergence of clinical strains of Stenotrophomonas maltophilia resistant to trimethoprime – sulfametoxazole in a Bulgarian university hospital. J Biomed Clin Research. 2008; 1:18-25.

Rodrıguez CH, Nastro M., CalvoJL, Fariña ME, Dabos L, Famiglietti A. In vitro activity of colistin against Stenotrophomonas maltophilia. J Global Antimicrob Resistance. 2014; 2: 316-7.

Sader HS, Jonesa RN. Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilli. Int J Antimicrob Agents. 2005; 25: 95–109.

Sader HS, Farrell DJ, Flamm RK, Jones RN. Antimicrobial susceptibility of Gramnegative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: Results from the SENTRY Antimicrobial Surveillance Program, 2009–2012 Int J Antimicrob Agents. 2014; 43: 328–34.

Samonis G, Karageorgopoulos DE, Maraki S, Levis P, Dimopoulou D, Sperno-vasilis NA, et al. Stenotrophomonas maltophilia infections in a general hospital: patient characteristics, antimicrobial susceptibility, and treatment outcome. PLoS ONE. 2012; 7:373-5.

Wu H, Wang JT, Shiau YR, Wang HY, Lauderdale TL, Chang SC. A multicenter surveillance of antimicrobial resistance on Stenotrophomonas maltophilia in Taiwan. J Microbiol Immunol Infect. 2012; 45:120-6.

Wu K, Yau YC, Matukas L, Waters V. Biofilm compared to conventional antimicrobial susceptibility of Stenotrophomonas maltophilia Isolates from cystic fibrosis patients. Antimicrob Agents Chemother. 2013; 57:1546–8.

Wu Y. and Shao Z. High-dosage tigecycline for Stenotrophomonas maltophilia bacteremia. Chin Med J. 2014; 127:3199.


Font Size